Literature DB >> 30127579

Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?

Kalasekhar Vijaysekharan1, Sachin Punatar1, Avinash Bonda1, Aniket Mohite1, Kartthik Shanmugam1, Lingaraj Nayak1, Anant Gokarn1, Navin Khattry1.   

Abstract

Entities:  

Year:  2018        PMID： 30127579      PMCID： PMC6081307          DOI： 10.1007/s12288-018-0929-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  8 in total

1.  Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.

Authors:  H U Schorlemmer; R R Bartlett; R Kurrle
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

Review 2.  Effects of leflunomide on immune responses and models of inflammation.

Authors:  R R Bartlett; H Anagnostopulos; T Zielinski; T Mattar; R Schleyerbach
Journal:  Springer Semin Immunopathol       Date:  1993

Review 3.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases.

Authors:  V Déage; D Burger; J M Dayer
Journal:  Eur Cytokine Netw       Date:  1998-12       Impact factor: 2.737

5.  Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Authors:  Attilio Olivieri; Franco Locatelli; Marco Zecca; Adele Sanna; Michele Cimminiello; Roberto Raimondi; Guido Gini; Nicola Mordini; Adriana Balduzzi; Pietro Leoni; Armando Gabrielli; Andrea Bacigalupo
Journal:  Blood       Date:  2009-04-29       Impact factor: 22.113

6.  Regulation of B cell function by the immunosuppressive agent leflunomide.

Authors:  K F Siemasko; A S Chong; J W Williams; E G Bremer; A Finnegan
Journal:  Transplantation       Date:  1996-02-27       Impact factor: 4.939

7.  Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide.

Authors:  C Mrowka; G H Thoenes; K H Langer; R R Bartlett
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

Review 8.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106
  8 in total
  1 in total

1.  The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.

Authors:  Andreas Muehler; Hella Kohlhof; Manfred Groeppel; Daniel Vitt
Journal:  Drugs R D       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.